{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:38:08Z","timestamp":1791999488532,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.urology.2023.02.019","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T20:33:39Z","timestamp":1677616419000},"page":"126-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Incremental Treatment Response by Cycle With Collagenase Clostridium Histolyticum for Peyronie's Disease: A Pooled Analysis of Two Phase 3 Trials"],"prefix":"10.1016","volume":"175","author":[{"given":"Matthew","family":"Ziegelmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinfang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genzhou","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"McLane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Landon","family":"Trost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2023.02.019_bib0001","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.sxmr.2019.06.004","article-title":"The etiology of Peyronie's disease: pathogenesis and genetic contributions","volume":"8","author":"Sharma","year":"2020","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.urology.2023.02.019_bib0002","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.sxmr.2019.02.004","article-title":"Pathophysiology and future therapeutic perspectives for resolving fibrosis in Peyronie's disease","volume":"7","author":"Milenkovic","year":"2019","journal-title":"Sex Med Rev"},{"key":"10.1016\/j.urology.2023.02.019_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150157","article-title":"The prevalence of Peyronie's disease in the United States: a population-based study","volume":"11","author":"Stuntz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.urology.2023.02.019_bib0004","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/282503","article-title":"A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States","volume":"2011","author":"DiBenedetti","year":"2011","journal-title":"Adv Urol"},{"key":"10.1016\/j.urology.2023.02.019_bib0005","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1111\/j.1743-6109.2008.00895.x","article-title":"The chronology of depression and distress in men with Peyronie's disease","volume":"5","author":"Nelson","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.02.019_bib0006","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/j.1743-6109.2008.00949.x","article-title":"Risk factors for emotional and relationship problems in Peyronie's disease","volume":"5","author":"Smith","year":"2008","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.02.019_bib0007","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1743-6109.2012.02999.x","article-title":"Psychological impact of Peyronie's disease: a review","volume":"10","author":"Nelson","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.02.019_bib0008","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/JU.0000000000001426","article-title":"Mental disorders in Peyronie's disease: a Swedish cohort study of 3.5 million men","volume":"205","author":"Kuja-Halkola","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.02.019_bib0009","series-title":"Endo Pharmaceuticals Inc. XIAFLEX (collagenase clostridium histolyticum) for injection, for intralesional use","year":"2021"},{"key":"10.1016\/j.urology.2023.02.019_bib0010","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/BF00255956","article-title":"Collagenase for Peyronie's disease experimental studies","volume":"10","author":"Gelbard","year":"1982","journal-title":"Urol Res"},{"key":"10.1016\/j.urology.2023.02.019_bib0011","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1021\/bi00377a004","article-title":"Limited proteolysis of type I collagen at hyperreactive sites by class I and IIClostridium histolyticum collagenases: complementary digestion patterns","volume":"26","author":"French","year":"1987","journal-title":"Biochemistry"},{"key":"10.1016\/j.urology.2023.02.019_bib0012","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0363-5023(96)80368-6","article-title":"Collagenase in the treatment of Dupuytren's disease: an in vitro study","volume":"21","author":"Starkweather","year":"1996","journal-title":"J Hand Surg"},{"key":"10.1016\/j.urology.2023.02.019_bib0013","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0022-5347(17)40920-7","article-title":"Isolation and characterization of collagen in Peyronie's disease","volume":"141","author":"Somers","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.02.019_bib0014","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.juro.2013.01.087","article-title":"Clinical efficacy, safety and tolerability of collagenase Clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies","volume":"190","author":"Gelbard","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.02.019_bib0015","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1016\/j.juro.2012.01.032","article-title":"Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease","volume":"187","author":"Gelbard","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.02.019_bib0016","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1111\/jsm.12312","article-title":"Baseline characteristics from an ongoing phase 3 study of collagenase clostridium histolyticum in patients with Peyronie's disease","volume":"10","author":"Gelbard","year":"2013","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.02.019_bib0017","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.jsxm.2017.08.008","article-title":"Safety and efficacy of collagenase clostridium histolyticum in the treatment of acute-phase Peyronie's disease","volume":"14","author":"Nguyen","year":"2017","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.02.019_bib0018","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.euf.2022.09.019","article-title":"Collagenase clostridium histolyticum treatment improves degree of curvature in Peyronie's disease with calcified plaques","volume":"9","author":"Masterson","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2023.02.019_bib0019","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.urology.2018.06.003","article-title":"Plaque calcification: an important predictor of collagenase Clostridium histolyticum treatment outcomes for men with Peyronie's disease","volume":"119","author":"Wymer","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.02.019_bib0020","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/JU.0000000000000032","article-title":"Intralesional collagenase Clostridium histolyticum causes meaningful improvement in men with Peyronie's disease: results of a multi-institutional analysis","volume":"201","author":"Hellstrom","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.02.019_bib0021","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.urology.2016.09.050","article-title":"Impact of number of cycles of collagenase Clostridium histolyticum on outcomes in patients with Peyronie's disease","volume":"100","author":"Anaissie","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.02.019_bib0022","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jsxm.2021.03.075","article-title":"Continuing collagenase Clostridium histolyticum injections among initial nonresponders results in significant curvature improvements in the majority of Peyronie's disease men","volume":"18","author":"Alom","year":"2021","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.02.019_bib0023","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/bju.13120","article-title":"Analysis of the clinical safety of intralesional injection of collagenase Clostridium histolyticum (CCH) for adults with Peyronie's disease (PD)","volume":"116","author":"Carson","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2023.02.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2017.05.004","article-title":"Safety profile of collagenase Clostridium histolyticum stratified by degree of penile curvature in patients with Peyronie disease","author":"Hellstrom","year":"2017","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.02.019_bib0025","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jsxm.2016.02.105","article-title":"Results of SMSNA survey regarding complications following intralesional injection therapy with collagenase clostridium histolyticum for Peyronie's disease","volume":"13","author":"Yafi","year":"2016","journal-title":"J Sex Med"},{"key":"10.1016\/j.urology.2023.02.019_bib0026","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41443-020-00383-7","article-title":"Conservative management of suspected fractures in men undergoing collagenase Clostridium histolyticum for Peyronie's disease is not associated with worsening of erectile function","volume":"34","author":"Sharma","year":"2022","journal-title":"Int J Impot Res"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523001826?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523001826?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T02:59:47Z","timestamp":1758769187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429523001826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":26,"alternative-id":["S0090429523001826"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2023.02.019","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incremental Treatment Response by Cycle With Collagenase Clostridium Histolyticum for Peyronie's Disease: A Pooled Analysis of Two Phase 3 Trials","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2023.02.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}